Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user is seeking advice on increasing graft survivability after a hair transplant, mentioning PRP, Mesotherapy, Stem Cell injections, and considering L-Arginine before starting Minoxidil. They are looking for ways to support blood flow before applying Minoxidil.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

Hair cloning claims by Dr. Gho are widely considered a scam, with skepticism about the effectiveness of his hair stem cell transplantation. Users suggest that if it were effective, wealthy individuals would opt for it over traditional methods like FUE transplants.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

Pelage Pharmaceuticals' PP405 is discussed with skepticism about its effectiveness in hair regrowth, with some users expressing doubt and others hopeful but cautious. Treatments like finasteride are mentioned as current options, but there's a general sentiment that a cure for hair loss is not imminent.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

A user is experiencing scalp flaking from a finasteride/minoxidil topical solution and considers using salicylic acid shampoo to remove propylene glycol residue. Another user suggests trying a leave-in conditioner to address dryness and flaking.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The new OGX thick and full shampoo formula makes hair poofy and soft, ruining its previous thickening effect. The user is seeking old bottles of the original formula.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

A user shared their experience with a second hair transplant by Dr. Gokhan Gur, focusing on the midscalp and crown with 1849 grafts. Their current treatment includes dutasteride, finasteride, oral and topical minoxidil, and Nizoral shampoo.

Microneedling and peptides like GHK-Cu may promote hair growth by improving blood supply to the scalp. There is skepticism about the effectiveness of KLOW, but some report positive results with GHK-Cu treatments.

Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

Bimatoprost and latanoprost are being considered for scalp hair growth, with concerns about side effects like skin darkening and fat loss. A user warns about potential chemical burns from latanoprost.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

PP405 shows promise in reactivating dormant hair follicles, with early trials indicating some success, but it is not yet a proven treatment for hair loss. Users are advised to be cautious with unverified versions, and further research is needed to confirm its effectiveness compared to treatments like minoxidil and finasteride.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.

PP405 is being compared to Minoxidil, with some suggesting it might be more effective since it's specifically designed for hair loss. Minoxidil was originally for blood pressure, and its hair growth effect is a side effect.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.